Literature DB >> 29501768

Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.

Mariam Abotaleb1, Peter Kubatka2, Martin Caprnda3, Elizabeth Varghese1, Barbora Zolakova4, Pavol Zubor5, Radka Opatrilova6, Peter Kruzliak7, Patrik Stefanicka8, Dietrich Büsselberg9.   

Abstract

Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antimetabolites; Antimitotic agents; Chemotherapy; DNA alkylating agents; Efficacy; Hormonal/endocrine therapy; Immunologic therapy; Ion modulators; Metastatic breast cancer; Resistance; Toxicity

Mesh:

Substances:

Year:  2018        PMID: 29501768     DOI: 10.1016/j.biopha.2018.02.108

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  31 in total

1.  A novel anticancer property of Lycium barbarum polysaccharide in triggering ferroptosis of breast cancer cells.

Authors:  Xing DU; Jingjing Zhang; Ling Liu; Bo Xu; Hang Han; Wenjie Dai; Xiuying Pei; Xufeng Fu; Shaozhang Hou
Journal:  J Zhejiang Univ Sci B       Date:  2022-04-15       Impact factor: 3.066

Review 2.  A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer.

Authors:  Muhammad Naeem; Muhammad Omer Iqbal; Humaira Khan; Muhammad Masood Ahmed; Muhammad Farooq; Muhammad Moeen Aadil; Mohamad Ikhwan Jamaludin; Abu Hazafa; Wan-Chi Tsai
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

Review 3.  The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

Authors:  Utpalendu Paul; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-03-02       Impact factor: 2.742

Review 4.  P2X7 receptor: a critical regulator and potential target for breast cancer.

Authors:  Xiaodi Zhu; Qianqian Li; Wei Song; Xiaoxiang Peng; Ronglan Zhao
Journal:  J Mol Med (Berl)       Date:  2021-01-23       Impact factor: 4.599

5.  Cytotoxic Phenanthrene, Dihydrophenanthrene, and Dihydrostilbene Derivatives and Other Aromatic Compounds from Combretum laxum.

Authors:  Eder Bisoli; Talita Vilalva Freire; Nídia Cristiane Yoshida; Walmir Silva Garcez; Lyara Meira Marinho Queiróz; Maria de Fátima Cepa Matos; Renata Trentin Perdomo; Fernanda Rodrigues Garcez
Journal:  Molecules       Date:  2020-07-10       Impact factor: 4.411

Review 6.  Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties.

Authors:  Sahu Henamayee; Kishore Banik; Bethsebie Lalduhsaki Sailo; Bano Shabnam; Choudhary Harsha; Satti Srilakshmi; Naidu Vgm; Seung Ho Baek; Kwang Seok Ahn; Ajaikumar B Kunnumakkara
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

Review 7.  Molecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers.

Authors:  Armando Cevenini; Stefania Orrù; Annamaria Mancini; Andreina Alfieri; Pasqualina Buono; Esther Imperlini
Journal:  Int J Mol Sci       Date:  2018-08-15       Impact factor: 5.923

8.  Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment.

Authors:  Zhaoyun Liu; Jing Shan; Qian Yu; Xinzhao Wang; Xiang Song; Fukai Wang; Chao Li; Zhiyong Yu; Jinming Yu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 9.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24

Review 10.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.